5月25日，据CDE官网消息，领泰生物医药（绍兴）有限公司联合申请药品“LT-002-158片”，获得临床试验默示许可，受理号CXHL2500271。
公示信息显示，药品“LT-002-158片”适应症：玫瑰痤疮（丘疹脓疱型）。
领泰生物医药（绍兴）有限公司，成立于2019年，位于绍兴市，是一家以从事研究和试验发展为主的企业。企业注册资本404.2576万人民币，实缴资本404.2576万人民币。
通过天眼查大数据分析，领泰生物医药（绍兴）有限公司共对外投资了1家企业，参与招投标项目1次，知识产权方面有商标信息4条，专利信息16条，此外企业还拥有行政许可5个。
主要股东信息显示，领泰生物医药（绍兴）有限公司由冯焱持股27.1574%、上海张科领弋扬帆创业投资中心（有限合伙）持股26.2209%、上海倍岸企业管理中心（有限合伙）持股11.2375%、YuanBio Venture Capital II L.P.持股8.4281%、上海扬本企业管理中心（有限合伙）持股8.4281%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.